Topiramate augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study

Journal of Psychopharmacology

Volumn 25, Issue 5, 2011, Pages 667-674

  Muscatello, Mra ^a   Bruno, A ^a   Pandolfo, G ^a   Mico U ^a   Bellinghieri, P M ^a   Scimeca, G ^a   Cacciola, M ^a   Campolo, D ^a   Settineri, S ^a   Zoccali, R ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Clozapine; residual symptoms; schizophrenia; topiramate

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; CLOZAPINE; FIBRINOGEN; FLUPENTIXOL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HALOPERIDOL; LORAZEPAM; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; TOPIRAMATE; TRIACYLGLYCEROL; URIC ACID;

ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRIEF PSYCHIATRIC RATING SCALE; CHOLESTEROL BLOOD LEVEL; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESISTANCE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBRINOGEN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SCHIZOPHRENIA; SYMPTOMATOLOGY; THERAPY EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COGNITION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955375973     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110372548     Document Type: Article

References (58)

1. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry. 1993 ; 163: 39-44 (Pubitemid 23355888)
2. Afshar H, Roohafza H, Mousavi G, et al. Topiramate add-on treatment in schizophrenia: a randomised, double blind, placebo-controlled clinical trial. J Psychopharmacol. 2008 ; 23: 157-162
3. Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia. 2000 ; 41: 1167-1178
4. Anand A, Charney DS, Oren DA, et al. Attenuation of neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry. 2000 ; 57: 270-276 (Pubitemid 30140436)
5. Andreasen N Scale for the Assessment of Negative Symptoms (SANS). Iowa: University of Iowa ; 1983 :
6. Andreasen N Scale for the Assessment of Positive Symptoms (SAPS). Iowa: University of Iowa ; 1984 :
7. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M. Symptoms of schizophrenia: methods, meanings, and mechanisms. Arch Gen Psychiatry. 1995 ; 52: 341-351
8. Arif H, Buchsbaum R, Weintraub D, et al. Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav. 2009 ; 14: 202-209
9. Arnone D. Review of the use of topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry. 2005 ; 4: 5-5
10. Barzman DH, Delbello MP. Topiramate fo co-occurring bipolar disorder and disruptive behavior disorders. Am J Psychiatry. 2006 ; 163: 1451-1452 (Pubitemid 44464427)
11. Chengappa KNR, Kupfer DJ, Parepally H, et al. A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Bipolar Disord. 2007 ; 9: 609-617 (Pubitemid 47365629)
12. Corssen G, Domino EF. Dissociative anaesthesia: further pharmacological studies and first clinical experience with the phencyclidine derivative CL-581. Anesth Analg. 1966 ; 45: 29-40
13. Deutsch SI, Rosse RB, Billingslea EN, Bellack AS, Mastropaolo J. Topiramate antagonizes MK-801 in an animal model of schizophrenia. Eur J Pharmacol. 2002 ; 449: 121-125
14. Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol. 2001 ; 24: 43-49 (Pubitemid 32176480)
15. Deutsch SI, Schwartz BL, Rosse RB, et al. Adjuvant topiramate administration: a pharmacologic strategy for addressing NMDA receptor hypofunction in schizophrenia. Clin Neuropharmacol. 2003 ; 26: 199-206 (Pubitemid 36951066)
16. Drapalski AL, Rosse RB, Peebles RR, et al. Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clin Neuropharmacol. 2001 ; 24: 290-294 (Pubitemid 32906716)
17. Duggal HS. Psychotic symptoms associated with topiramate: cognitive side effects or worsening of psychosis?. J Clin Psychiatry. 2004 ; 65: 1145-1145
18. Dursun SM, Deakin JFW. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: A naturalistic case-series outcome studies. J Psychopharmacol. 2001 ; 15: 297-301 (Pubitemid 34024249)
19. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry. 2000 ; 45: 198-198
20. Farber NB, Kim SH, Dikranian K, Jiang XP, Heinkel C. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry. 2002 ; 7: 32-43 (Pubitemid 34087877)
21. Farber NB, Newcomer JW, Olney JW. Glycine agonists: what can they teach us about schizophrenia?. Arch Gen Psychiatry. 1999 ; 56: 13-17 (Pubitemid 29055045)
22. Gilliam FG, Veloso F, Bomhof MA, et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology. 2003 ; 60: 196-202 (Pubitemid 36152008)
23. Gobbi G, Gaudreau PO, Leblanc N. Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. J Clin Psychopharmacol. 2006 ; 26: 467-473 (Pubitemid 44401465)
24. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 2001 ; 158: 1367-1377 (Pubitemid 32847232)
25. Gray JA, Risch SC. When clozapine is not enough. Augment with lamotrigine?. Curr Psychiatr. 2009 ; 8: 41-46
26. Halberstadt AL. The phencyclidine-glutamate model of schizophrenia. Clin Neuropharmacol. 1995 ; 18: 237-249
27. Haroutunian V, Dracheva S, Davis K. Neurobiology of glutamatergic abnormalities in schizophrenia. Clin Neurosci Res. 2003 ; 3: 67-76 (Pubitemid 36975298)
28. Heaton R, Chelune G, Talley J, Kay G, Curtis G Winsconsin Card Sorting Test Manual. Odessa, FL: Psychological Resources ; 1993 :
29. Hosák L, Libiger J. Antiepileptic drugs in schizophrenia: a review. Eur Psychiatry. 2002 ; 17: 371-378 (Pubitemid 35429270)
30. Janowsky DS, Kraus JE, Barnhill J, Elamir B, Davis JM. Effects of topiramate on aggressive, self-injourious, and disruptive/destructive behaviours in the intellectually disabled: an open-label retrospective study. J Clin Psychopharmacol. 2003 ; 23: 500-504 (Pubitemid 37138635)
31. Jardemark KE, Konradsson Å, Schilström B, Marcus MM, Svensson TH. Differential effects of topiramate on prefrontal glutamatergic transmission when combined with raclopride or clozapine. Synapse. 2009 ; 63: 913-920
32. Javitt DC, Zukin SR Schizophrenia research progress. Schulz SC Tamminga CA, ed. New York: Raven Press ; 1991: 12-19.
33. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1999 ; 20: 201-225 (Pubitemid 29067401)
34. John JP, Khanna S, Thennarasu S, Reddy S. Exploration of dimensions of psychopathology in neuroleptic-naïve patients with recent-onset schizophrenia/schizophreniform disorder. Psychiatry Res. 2003 ; 121: 11-20 (Pubitemid 37311384)
35. Kang HC, Eun BL, Wu Lee C, et al. The effects on cognitive function and behavioural problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia. 2007 ; 48: 1716-1723 (Pubitemid 47352877)
36. Kober D, Gabbard GO. Topiramate-induced psychosis. Am J Psychiatry. 2005 ; 162: 1542-1542
37. Kurtz MM. Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophr Res. 2005 ; 74: 15-26 (Pubitemid 40203180)
38. Lee S, Sziklas V, Andermann F, et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia. 2003 ; 44: 339-347 (Pubitemid 36343764)
39. Lin YH, Liu CY, Hsiao MC. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Psychiatry Clin Neurosci. 2005 ; 59: 613-615
40. McDaniel WW, Spiegel DR, Sahota AK. Topiramate effect in catatonia: a case series. J Neuropsychiatry Clin Neurosci. 2006 ; 18: 234-238
41. Millson RC, Owen JA, Lorberg GW, Tackaberry L. Topiramate for refractory schizophrenia. Am J Psychiatry. 2002 ; 159: 675-675
42. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995 ; 52: 998-1007
43. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962 ; 10: 799-812
44. Paixão José RJ, Cairns A, Babbs C. Topiramate-induced psychosis in two members of the one family: a case report. J Med Case Reports. 2008 ; 2: 195-195
45. Peralta V, Cuesta MJ. Dimensional structure of psychotic symptoms: an item-level analysis of SAPS and SANS symptoms in psychotic disorders. Schizophr Res. 1999 ; 38: 13-26 (Pubitemid 29333597)
46. Ramos Rios R, Martinez Formoso S, Arrojo Romero M, Ecenarro Tome P, Arauxo Vilar A. Topiramate in OCD comorbid with impulsive behaviour disorders. Eur Psychiatry. 2007 ; 22: S293 - S294.
47. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000 ; 41: S3 - S9
48. Spreen O, Benton AL Neurosensory Center Comprehensive Examination for Aphasia (NCCEA). Victoria: University of Victoria Neuropsychology Laboratory ; 1977 :
49. Tamminga CA. Glutamatergic aspects of schizophrenia. Br J Psychiatry. 1999 ; 174: 12-15
50. Tamminga CA, Holcomb HH. Phenotype of schizophrenia: a review and formulation. Mol Psychiatry. 2005 ; 10: 27-39 (Pubitemid 40139587)
51. Thompson PJ, Baxendale SA, Duncan JS, Sander JW. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry. 2000 ; 69: 636-641
52. Tiihonen J, Hallikainen T, Ryynänen O-P, et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry. 2003 ; 54: 1241-1248 (Pubitemid 37464870)
53. Tiihonen J, Halonen P, Wahlbeck K, et al. Topiramate add-on in treatment resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry. 2005 ; 66 (8). 1012-1015
54. Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2009 ; 109: 10-14
55. Trenerry MR, Crosson B, DeBoe J, Leber WR Stroop Neuropsychological Screening Test. Odessa FL: Psychological Assessment Resources, Inc ; 1989 :
56. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2005 ; 72: 225-234 (Pubitemid 39550993)
57. Ulas J, Cotman CW. Excitatory amino acid receptors in schizophrenia. Schizophr Bull. 1993 ; 19: 105-117 (Pubitemid 23073558)
58. Zoccali R, Muscatello MR, Bruno A, et al. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr Res. 2007 ; 93: 109-116 (Pubitemid 46817934)